Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
22/05/2026 11:26
May 22 (Reuters) - Brii Biosciences Ltd 2137.HK: AS OF MAY 22, ARBITRATION BETWEEN BRII AND VIR REMAINS IN EARLY STAGES WITH NO RESOLUTION CONSIDERS ELEBSIRAN PROGRAM FUTURE UNCERTAIN DUE TO ONGOING DISPUTE CANNOT INVEST IN PHASE 3 CLINICAL STUDY OF ANY ELEBSIRAN-CONTAINING COMBINATION THERAPY FOR HBV UNTIL CLAIMS ARE RESOLVED Further company coverage: 2137.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR